[Pancreatic disease in patients with HIV treated with didanosine (DDI)].
Pancreatic involvement has been studied in 70 HIV infected patients, in diverse stages, that were treated with didanosine (ddI), both as monotherapy or associated to zidovudine; 38% of patients presented adverse reaction that obliged to withdraw the medication: pancreatitis (4%), hyperamylasemia (21%) and abdominal pain and/or diarrhea (12%). The possible causes in presentation of adverse effects were evaluated: route of infection, stage of HIV infection, use of pentamidine or trimethoprim-sulfamethoxazole for preventing Pneumocystis carinii pneumonia, administration of ddI in monotherapy or in combined form with zidovudine, time of treatment and level of CD4 lymphocytes. The outcome of adverse effects is related significantly only with the most advanced stage of HIV infection.
Ortega González
E
E
Sección de Enfermedades Infecciosas, Hospital General Universitario, Valencia.
Martín Herrera
A
A
López de Medrano
V
V
de Lelis
F P
FP
Ronda Gasulla
F A
FA
Gil Egea
M
M
Ballester Belda
E
E
Herrera Ballester
A
A
D000208:Acute Disease; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D010182:Pancreatic Diseases / Q000139:chemically induced*; D010195:Pancreatitis / Q000139:chemically induced; D015215:Zidovudine / Q000008:administration & dosage
D000998:Antiviral Agents; D015215:Zidovudine; D016049:Didanosine
Afectación pancreática en pacientes VIH tratados con didanosina (DDI).